Tempus AI

Tempus AI Down 12.9% Since Last Earnings Report: Can It Rebound?

Tempus AI Collaborates with Daiichi Sankyo to Accelerate Oncology Drug Development

Tempus AI's 15min chart shows Bollinger Bands narrowing, KDJ death cross.

ARK Innovation ETF

Circle

CRISPR Therapeutics

ARKK Sees Significant Outflows Amidst Declines in CRSP, CRCL, and TEM

Tempus AI: MACD Death Cross, KDJ Death Cross Triggers in 15min Chart

Catalyst<ul> <li>Recent MACD Golden Cross signals in late March indicate potential rebound momentum for TEM.</li></ul>Risk<ul> <li>Overall fund flows show negative trends across small, medium, large, and extra-large order buckets.</li></ul>

Key Factors

Tempus AI reported a Q4 2025 adjusted loss of 4 cents per share with revenues of $367.2 million, beating analyst estimates.Tempus AI entered a strategic collaboration with Daiichi Sankyo to accelerate oncology drug development using its AI foundation models.

Recent Updates

TEM News